Cancer-related fatigue: the Australian general practice management guide

What makes cancer-related fatigue different

Cancer-related fatigue (CRF) is the most commonly reported and most distressing side effect of cancer and cancer treatment. The Australian Institute of Health and Welfare estimates there are approximately 1.4 million cancer survivors in Australia — with CRF affecting around 150,000 of them with ongoing significant fatigue at any given time, and this number grows as survivorship improves.

What distinguishes CRF from ordinary tiredness is its defining features: persistent, subjective, and not proportional to activity; and — critically — not reliably relieved by rest. Patients describe it as a profound, whole-body exhaustion that does not respond to sleep the way ordinary tiredness does. This last feature often delays recognition: patients and clinicians may assume that rest should fix it, and feel confused or frustrated when it does not.

CRF occurs in three main phases: treatment-phase (during chemotherapy, radiotherapy, surgery, immunotherapy, or hormonal therapy — prevalence 70–100%); post-treatment (persisting three months or more after curative-intent therapy — prevalence 30–40% at one year); and long-term survivorship (beyond two years post-treatment — approximately 20%).

The GP role in CRF is central: shared-care survivorship management, systematic reversible-cause screening, exercise prescription, psychosocial support coordination, and cardiotoxicity surveillance for appropriate survivors.

A. Core clinical — the AU general-practice framework

Screening and measurement at every cancer review

Use a validated brief tool at each contact. The numeric rating scale (0–10) — anchored on “interference with daily activities” — is the simplest and most widely applied: mild 0–3, moderate 4–6, severe 7–10. The Brief Fatigue Inventory (BFI, 9 items) and FACIT-Fatigue (13 items) provide more granular serial monitoring. Document scores in the medical record to track trajectory across consultations.

Per NCCN CRF v.2.2024, ESMO 2020/2024, and ASCO Bower 2014/2022: screen at every cancer visit, quantify severity, and systematically look for reversible causes before attributing fatigue to cancer itself.

The reversible-cause screen

Many concurrent conditions amplify CRF or mimic it. Investigate and correct at every review:

Anaemia — haemoglobin, MCV, ferritin, iron studies, transferrin saturation, reticulocyte count. Functional iron deficiency is common during chemotherapy even when stores are not depleted. Iron replacement (oral or intravenous depending on severity and tolerance) can be transformative.

Thyroid dysfunction — TSH ± free T4; particularly important post-neck or mediastinal radiotherapy (hypothyroidism in 10–40%), and in patients receiving immune checkpoint inhibitors (thyroiditis is a common immune-related adverse event).

Adrenal insufficiency — 8 am serum cortisol in patients on long-term steroids being tapered, or those who received immunotherapy with suspected hypophysitis. Postural hypotension, hyponatraemia, and hyperkalaemia are clues.

Hypogonadism — testosterone in men on androgen deprivation therapy (ADT) for prostate cancer; oestradiol/FSH in women with chemotherapy-induced premature ovarian insufficiency.

Vitamin deficiencies — vitamin D (25-OH), B12, folate; correct if low.

Electrolyte abnormalities — calcium, magnesium, phosphate; particularly relevant during chemotherapy cycles.

Sleep disorder — insomnia, hot flushes, nocturia, pain-disrupted sleep. Screen for obstructive sleep apnoea (Epworth Sleepiness Scale, STOP-BANG) — OSA is not less common in cancer survivors.

Depression and anxiety — PHQ-9 ≥10 or GAD-7 ≥10 triggers a mental health care plan. Distinguish anhedonia-driven low mood (depression) from energy-limited functional fatigue (CRF) — both may coexist.

Medication review — opioids, gabapentinoids, antihistamines, benzodiazepines, antidepressants (some), beta-blockers, antiemetics (prochlorperazine, metoclopramide), and steroids on withdrawal can all amplify fatigue.

Cardiotoxicity — post-anthracycline (doxorubicin, epirubicin), trastuzumab, or chest/left breast radiotherapy; fatigue may be the first manifestation of subclinical left ventricular dysfunction; see cardiotoxicity section below.

History

• Onset, duration, trajectory — predates, started with, or is worsening after treatment; relationship to chemotherapy cycles (often a predictable nadir pattern)
• Post-exertional malaise (PEM) — if fatigue worsens significantly after minimal exertion and takes 24–48 hours to recover, distinguish from ME/CFS or long COVID where PEM is the cardinal feature; standard CRF exercise-escalation recommendations may need modification
• Functional impact — work, household, ADLs, exercise tolerance, relationships; Karnofsky or ECOG performance status
• Social and financial — CRF-associated work incapacity; Centrelink JobSeeker (medical certificate), Disability Support Pension if sustained; Cancer Council Australia 13 11 20 financial counselling

Examination

• Performance status — ECOG 0–4; Karnofsky 100–0; document at each visit
• Vital signs — postural blood pressure and heart rate (deconditioning, autonomic dysfunction); SpO₂
• Body composition — weight trend, calf circumference, grip strength (sarcopenia screen)
• Anaemia signs — pallor, conjunctival pallor, tachycardia, ejection flow murmur
• Cardiotoxicity signs — raised jugular venous pressure, peripheral oedema, S3, pulmonary crackles, displaced apex
• Lymphadenopathy — recurrence screen; correlate with B symptoms
• Neurological — stocking-glove sensory loss (chemotherapy-induced peripheral neuropathy); proximal weakness (steroid myopathy, paraneoplastic)
• Mental state — affect, cognition, suicidality assessment

B. Exercise and psychosocial interventions — the evidence backbone

Exercise: Category 1 evidence

Exercise is the most rigorously supported intervention for CRF. Cramp & Byron-Daniel Cochrane 2017 — 56 RCTs — demonstrated approximately 25% reduction in fatigue severity across tumour groups, during and after treatment. Mishra Cochrane 2012 corroborated these findings for quality of life more broadly. ASCO 2022 Bower, NCCN, and ESMO all classify exercise as Category 1 / Strong recommendation — the highest evidence tier in oncology guidelines.

Prescription:

• Aerobic — 150 minutes per week moderate intensity (3–5 MET: brisk walking, swimming, stationary cycling) or 75 minutes vigorous; begin at achievable level and progress by 10% per week
• Resistance — two sessions per week, major muscle groups, 8–12 repetitions × 2–3 sets; critical for preserving muscle mass and managing sarcopenia
• Flexibility and balance as tolerated

Refer to an accredited exercise physiologist under the General Practice Chronic Conditions Management Plan (GPCCMP) — item 10954, five sessions per year (ten for Aboriginal and Torres Strait Islander patients). Even patients with poor performance status benefit from adapted, supervised in-bed or chair-based exercise.

Psychosocial interventions

CBT for fatigue and sleep (Goedendorp Cochrane 2009) — moderate effect; particularly useful when sleep disturbance, catastrophising, and fear of recurrence dominate; refer via Mental Health Care Plan (MHCP), items 2715/2717.

Mindfulness-based stress reduction (MBSR) / mindfulness-based cancer recovery — eight-week structured programmes; reduces fatigue, psychological distress, and sleep disruption; available as group programmes in major cities and online.

Psychoeducation — explaining CRF biology, normalising the experience, and correcting the “just push through” misconception. Pacing and energy conservation frameworks are more effective than willpower alone.

What does not work and what to avoid

Methylphenidate — broadly negative in ambulatory (non-advanced) cancer patients (Bruera JCO 2003); NCCN allows limited use in advanced/palliative disease only. Not PBS-approved for CRF.

Modafinil — phase 3 negative (Jean-Pierre Cancer 2010; Spathis JCO 2014); not recommended for cancer survivors.

High-dose antioxidant supplementation during chemotherapy or radiotherapy — theoretical and observed interference with treatment efficacy; avoid.

IV vitamin C during chemotherapy or immunotherapy — potential for interference with antineoplastic activity and risk of hyperoxaluria and renal stone formation; avoid.

American ginseng (Panax quinquefolius, not P. ginseng) — Barton/Wang JNCI 2013 showed modest benefit at 8 weeks. A reasonable patient-driven trial using a TGA-listed preparation; review at four to eight weeks; note warfarin, antiplatelet, and hypoglycaemic interactions.

C. Cardiotoxicity surveillance in survivors

Who needs cardiac surveillance

Anthracycline chemotherapy (doxorubicin, epirubicin, idarubicin — cumulative dose-dependent cardiotoxicity), trastuzumab (HER2-targeted; potentially reversible), and chest or left breast radiotherapy (constrictive pericarditis, ischaemic heart disease, and valvular disease, often decades after treatment) can all impair cardiac function. Fatigue may be the presenting symptom of subclinical cardiac dysfunction before overt heart failure develops.

Surveillance per Plana ASE 2014 and cardio-oncology consensus:

• Baseline echocardiogram before starting anthracycline or trastuzumab regimens
• During treatment — repeat at completion of anthracycline course; at 6 and 12 months during trastuzumab
• Post-treatment — annual echocardiogram for five years in higher-cumulative-dose anthracycline survivors; then 2-yearly as part of long-term survivorship

MBS item 55113 (echocardiogram, specialist-billed) is rebatable for cardiotoxicity surveillance. Request via cardiology or through the treating oncologist’s survivorship plan.

When to act on cardiac concern

New or worsening exertional dyspnoea, orthopnoea, ankle oedema, or palpitations in an anthracycline or chest-RT survivor should trigger urgent echocardiogram and cardiology referral — do not wait for the routine surveillance interval.

LVEF below 50%, or a drop of more than 10 percentage points on surveillance echo warrants cardiology input; cardioprotective therapy (ACE inhibitor or beta-blocker) may be initiated to stabilise or recover function.

D. Australian operations

MBS items

• Standard GP consultations — items 23, 36, 44; CRF reviews typically warrant Level C or D given complexity
• GPCCMP — item 965 (preparation), 967 (review every 3 months); cancer and cancer survivorship qualifies as a chronic condition; direct allied health referral (exercise physiologist, psychologist, dietitian, OT — five sessions per year, ten for Aboriginal and Torres Strait Islander patients)
• Mental Health Care Plan (MHCP) — items 2715/2717; for comorbid depression, anxiety, or fear of recurrence; ten psychology sessions per year via Better Access
• Case conferencing with oncologist and allied health — items 132/133
• Aboriginal and Torres Strait Islander Health Assessment — item 715
• Telehealth — items 91790/91891; especially valuable for housebound, immunocompromised, or regionally isolated survivors
• Echocardiogram — item 55113 for cardiotoxicity surveillance

PBS items

• Oral iron — general/OTC
• Parenteral iron (Ferinject / Monofer) — Authority Required; for documented iron deficiency intolerant to or failed oral iron
• Thyroxine — general
• Vitamin D (cholecalciferol) — general for documented deficiency
• Antidepressants (SSRI / SNRI) — general, for documented depression or anxiety; not for CRF alone
• Z-drugs (zolpidem / zopiclone) — Authority Required; short-term insomnia only
• Pregabalin / gabapentin — Authority Required; for neuropathic pain (chemotherapy-induced peripheral neuropathy); SafeScript/RTPM
• Opioids — Authority Required; SafeScript; deprescribing plan if long-term

Financial and social supports

Cancer Council Australia 13 11 20 — financial counselling, practical support, accommodation assistance for rural patients travelling for treatment.

Centrelink — JobSeeker (GP medical certificate for temporary incapacity); Disability Support Pension for sustained severe functional impairment; document with medical evidence.

DVA Gold and White Card — eligible treatment-related CRF; streamlined allied health access.

NDIS — rarely applicable for CRF in isolation, but may apply when functional impairment from cancer treatment occurs before age 65.

E. Special populations

Older adults and frailty. CRF overlaps with, and is amplified by, sarcopenia and frailty. Exercise prescription must be adapted — start at very low intensity, focus on falls prevention and balance, and progress cautiously. Comprehensive Geriatric Assessment identifies and targets frailty components alongside CRF management. Polypharmacy review (deprescribing sedating medications) is often as impactful as adding new agents.

Haematological malignancy and bone marrow transplant. Post-transplant CRF is among the most severe and persistent. Graft-versus-host disease, prolonged immunosuppression, and transplant-related endocrine effects compound fatigue. Multidisciplinary survivorship input from the transplanting service is essential in the GP shared-care model.

Breast cancer on endocrine therapy. Aromatase inhibitors and tamoxifen carry significant fatigue burden, particularly via oestrogen deprivation and musculoskeletal effects. Hot flushes, sleep disruption, and joint pain all contribute. Optimising symptom management within the constraints of endocrine therapy continuation is the priority.

Aboriginal and Torres Strait Islander patients. Cancer mortality rates are higher and survival shorter in Indigenous Australians. CRF burden is assumed to be equivalent or greater, and access to exercise physiology, survivorship clinics, and mental health services is more limited in remote areas. Telehealth-delivered exercise coaching and culturally safe support services help address this gap. Item 715 and GPCCMP should be used proactively.

Long COVID and ME/CFS overlap. When post-exertional malaise (PEM) — fatigue worsening 24 hours after minimal exertion, lasting 24–48 hours — is the dominant feature, distinguish carefully from standard CRF. Standard incremental exercise escalation that helps CRF may worsen PEM-predominant presentations; pacing and heart-rate monitoring rather than progressive overload is the appropriate approach.

When to escalate

Refer urgently for recurrence workup when: unintentional weight loss ≥5% over 3 months, B symptoms (drenching night sweats, fever), new bone pain, new lymphadenopathy, rising LDH or calcium, or new neurological symptoms.

Refer for urgent cardiac assessment when: new exertional dyspnoea or orthopnoea, ankle oedema, sustained palpitations, or any cardiac symptom in a patient who received anthracyclines, trastuzumab, or chest radiotherapy.

Refer urgently for mental health crisis: suicidal ideation, severe depression with functional collapse, severe adjustment disorder.

What this article is and is not

This is general health information based on current evidence in oncology survivorship — NCCN, ESMO, ASCO, Cancer Council Australia, Therapeutic Guidelines, and major Cochrane reviews — and is intended to prepare the environment for informed conversations with treating teams. It is not personal medical advice. Decisions about cancer management, cardiac surveillance, and medication changes should always be made with the patient’s oncologist, GP, and relevant specialists.

For consumer resources: Cancer Council Australia 13 11 20, HealthDirect, Better Health Channel.

For mental health support: Beyond Blue 1300 22 4636, Lifeline 13 11 14.

---

Sources cited

1. Cancer Council Australia — Living well after cancer / Fatigue (2023)
2. AIHW — Cancer Data in Australia 2024
3. NCCN — Cancer-Related Fatigue v.2.2024
4. ASCO Bower JE et al — CRF guideline (J Clin Oncol 2014, updated 2022)
5. ESMO Fabi A et al — CRF Clinical Practice Guidelines (Ann Oncol 2020/2024)
6. Therapeutic Guidelines (eTG) — Palliative and Supportive Care
7. Cramp F, Byron-Daniel J — Exercise for CRF (Cochrane 2017)
8. Mishra SI et al — Exercise and QoL for cancer survivors (Cochrane 2012)
9. Goedendorp MM et al — Psychosocial interventions for CRF (Cochrane 2009)
10. Plana JC et al — Cardiac imaging during and after cancer therapy (J Am Soc Echocardiogr 2014)
11. Barton DL et al — American ginseng for CRF (JNCI 2013)
12. Australian Medicines Handbook (AMH)
13. Cancer Australia — Australian Cancer Plan 2024
14. HealthDirect
15. Better Health Channel